First quarter earnings event for Tsumura stock
Tsumura (TSE:4540) drew fresh attention after reporting first quarter earnings to 30 June 2026, with sales of ¥49,704 million and net income of ¥6,457 million from continuing operations.
See our latest analysis for Tsumura.
Against this earnings backdrop, Tsumura’s share price return has softened in the short term, with the stock down 3.4% over 30 days and 9.1% year to date, while longer term total shareholder returns of 7.9% over one year and 53.3% over three years suggest the broader trend has been more supportive.
If this earnings update has you reassessing your watchlist, it could be a good moment to widen your search using the 12 top founder-led companies
Tsumura’s earnings momentum contrasts with the recent share price pullback. The key issue now is whether that combination tilts the risk reward toward buyers or if expectations already reflect the good news on profits.
Preferred P/E multiple for Tsumura: Is it justified?
Tsumura trades on a P/E of 9.2x, which screens as inexpensive compared to several benchmarks, even after the recent share price pullback to ¥3,748.
The P/E multiple compares the current share price to earnings per share. For a pharmaceutical business like Tsumura, it gives a quick sense of how the market is valuing its current profit base relative to peers.
Here, the company screens as good value on several fronts. The P/E of 9.2x is below both the Japan Pharmaceuticals industry average of 15.2x and the peer average of 15.8x. It is also below an estimated fair P/E ratio of 16.6x that regression analysis points to as a level the market could reasonably move toward if sentiment or expectations shift.
For investors comparing valuation signals, this combination of a lower current P/E and a higher fair P/E estimate suggests the market is pricing Tsumura more conservatively than these reference points indicate. Explore the SWS fair ratio for Tsumura
Result: Price-to-earnings of 9.2x (UNDERVALUED)
However, Tsumura still faces risks if annual net income growth remains flat and overseas sales, particularly in China, fail to build on current contribution levels.
Find out about the key risks to this Tsumura narrative.
Another view on Tsumura’s value
The SWS DCF model presents a very different picture for Tsumura. It suggests a future cash flow value of ¥13,706.21 per share compared with the current ¥3,748 price, which implies the stock screens as very undervalued. The question for you is how much weight to put on long term cash flow assumptions.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Tsumura for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 26 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With mixed signals around Tsumura’s valuation and outlook, it helps to weigh both sides quickly and ground your own judgement in the underlying data using the 3 key rewards and 2 important warning signs
Looking for more investment ideas beyond Tsumura?
If Tsumura has sharpened your focus, do not stop there. Broader research can help you stress test your thinking and spot alternatives that fit your style.
- Target potential mispricing opportunities by scanning companies that currently screen as 26 high quality undervalued stocks.
- Prioritise stability and capital preservation by reviewing 58 resilient stocks with low risk scores that may offer more resilient profiles.
- Hunt for compelling stories off the radar by checking the screener containing 71 high quality undiscovered gems that align with your return and risk preferences.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com